Alveus Therapeutics
PrivateLast Round
Series A
Extension
Feb 24, 2026
Total Funding Raised
$234M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Alveus Therapeutics is a biotechnology company developing next-generation therapies for obesity and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alveus Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Alveus Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Feb 24, 2026 | ||||
| Series A | Jan 8, 2026 |
Key People
Founding team and executive leadership
Alveus Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Avego Management | Series A, Series A Extension |
| Omega Funds | Series A, Series A Extension |
| Andera Partners | Series A, Series A Extension |
| New Rhein Healthcare Investors | Series A, Series A Extension |
| Novo Holdings | Series A Extension |
| Sanofi Ventures | Series A Extension |
| Jeito Capital | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 4, 2026
Grew 22% QoQ, from 27 to 33 employees.
- Jan 29, 2026
Developing new active ingredient for obesity treatment with InterAx.
Alveus Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Alveus Therapeutics's valuation, stock price, and market status.